Kedrion SpA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Kedrion SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013232
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kedrion SpA (Kedrion) collects and fractionates blood plasma to develop, produce and distribute plasma-derived therapies. The company’s products are used for the treatment of rare and serious disorders such as hemophilia, immune deficiency and neurological disorders. It also offers products for the treatment of orphan diseases. Kedrion also offers contract manufacturing services, technology transfer services and biological safety center services. The company works in partnership with Italian National Health Service to achieve self-sufficiency in plasma-derived therapies. It has manufacturing plants in Italy, Hungary and the US. The company has operational presence in Asia, Europe, North America and South America. Kedrion is headquartered in Barga, Lucca, Italy.

Kedrion SpA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kedrion SpA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Kedrion SpA, Medical Devices Deals, 2011 to YTD 2017 9
Kedrion SpA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kedrion SpA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Kedrion Acquires RhoGAM Line Of Products From Ortho-Clinical Diagnostics 11
Kedrion Completes Acquisition Of Fractionation Facility And Plasma Collection Centers From Grifols 12
Partnerships 13
National Immunobiological, Pharmstandard and Kedrion Biopharma form Joint Venture 13
Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 14
Kamada Enters into Co-Marketing Agreement with Kedrion 15
Licensing Agreements 16
United Biotech Enters into Licensing Agreement with Kedrion 16
Debt Offering 17
Kedrion Raises USD397 Million in Public Offering of 3% Bonds Due 2022 17
Kedrion Raises USD514 Million in Private Placement of Bonds 18
Acquisition 19
Kedrion Completes Acquisition Of Somerset Labs From Ortho-Clinical Diagnostics 19
Fondo Strategico Italiano Acquires 18.6% Stake In Kedrion From Sestant For US$188 Million 20
Kedrion SpA – Key Competitors 21
Kedrion SpA – Key Employees 22
Kedrion SpA – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Kedrion SpA, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kedrion SpA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kedrion SpA, Deals By Therapy Area, 2011 to YTD 2017 8
Kedrion SpA, Medical Devices Deals, 2011 to YTD 2017 9
Kedrion SpA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kedrion Acquires RhoGAM Line Of Products From Ortho-Clinical Diagnostics 11
Kedrion Completes Acquisition Of Fractionation Facility And Plasma Collection Centers From Grifols 12
National Immunobiological, Pharmstandard and Kedrion Biopharma form Joint Venture 13
Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 14
Kamada Enters into Co-Marketing Agreement with Kedrion 15
United Biotech Enters into Licensing Agreement with Kedrion 16
Kedrion Raises USD397 Million in Public Offering of 3% Bonds Due 2022 17
Kedrion Raises USD514 Million in Private Placement of Bonds 18
Kedrion Completes Acquisition Of Somerset Labs From Ortho-Clinical Diagnostics 19
Fondo Strategico Italiano Acquires 18.6% Stake In Kedrion From Sestant For US$188 Million 20
Kedrion SpA, Key Competitors 21
Kedrion SpA, Key Employees 22
Kedrion SpA, Subsidiaries 23

★海外企業調査レポート[Kedrion SpA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BB&T Corporation:企業のM&A・事業提携・投資動向
    BB&T Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BB&T Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • NAPEC Inc. (NPC)-エネルギー分野:企業M&A・提携分析
    Summary NAPEC Inc. (NAPEC), formerly CVTech Group Inc., is an energy services company that provides construction and maintenance services. It builds and maintains electrical transmission and distribution systems, solar panel farms, and natural gas networks. The company installs gas-powered and elect …
  • Attijariwafa Bank SA (ATW):企業の財務・戦略的SWOT分析
    Attijariwafa Bank SA (ATW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • G Adventures Inc:企業の戦略・SWOT・財務情報
    G Adventures Inc - Strategy, SWOT and Corporate Finance Report Summary G Adventures Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Genera Biosystems Ltd (GBI)-製薬・医療分野:企業M&A・提携分析
    Summary Genera Biosystems Ltd (GBL) is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pat …
  • CapitaLand Limited:企業のM&A・事業提携・投資動向
    CapitaLand Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CapitaLand Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Fichtner GmbH & Co KG:企業の戦略的SWOT分析
    Fichtner GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Total SA (FP):石油・ガス:M&Aディール及び事業提携情報
    Summary Total SA (Total) is an integrated global energy company that discovers, produces, refines and markets oil and gas, and also manufactures petrochemicals. It carries out drilling, oil and gas production, processing, transportation, refining and petrochemical production, storage and distributio …
  • Denator AB:医療機器:M&Aディール及び事業提携情報
    Summary Denator AB (Denator) is a provider of heat stabilization technology solutions that markets, develops, and sells instruments and consumables to address needs in the life science and clinical research markets. The company provides products such as stabilizor peptide extraction kits, stabilizor …
  • G1 Therapeutics Inc (GTHX):製薬・医療:M&Aディール及び事業提携情報
    Summary G1 Therapeutics Inc (G1 Therapeutics), formerly G Zero Therapeutics Inc, is a clinical stage biopharmaceutical company that discovers, develops and commercializes therapeutics for the treatment of cancer. The company’s pipeline products include trilaciclib (G1T28), a CDK4/6 inhibitor to pres …
  • Banca Monte dei Paschi di Siena S.p.A.:戦略・SWOT・企業財務分析
    Banca Monte dei Paschi di Siena S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Banca Monte dei Paschi di Siena S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Fomento de Construcciones y Contratas SA (FCC):電力:M&Aディール及び事業提携情報
    Summary Fomento de Construcciones y Contratas SA (FCC) is a citizen services company. It provides services in environmental, water, and infrastructure development sectors. The company manages and treats domestic and industrial waste; provides integrated water management services; and designs, develo …
  • LiNiu Technology Group:企業の戦略・SWOT・財務分析
    LiNiu Technology Group - Strategy, SWOT and Corporate Finance Report Summary LiNiu Technology Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Carl Zeiss Meditec Inc.:医療機器:M&Aディール及び事業提携情報
    Summary Carl Zeiss Meditec Inc (Carl Zeiss Meditec), a subsidiary of Carl Zeiss Meditec AG is a medical technology company that manufactures and markets various healthcare products. The company provides ophthalmology and optometry products, neurosurgery products, ENT products, spine surgery products …
  • Cambridge Research Biochemicals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Cambridge Research Biochemicals Ltd (CRB) is a provider of custom peptide and custom antibody producer for research activities. The company offers products such as stock peptides, peptide nucleic acid, florescent dyes, and immunological products and labeling kits. Its immunological products …
  • TTM Technologies, Inc.:企業の戦略・SWOT・財務情報
    TTM Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary TTM Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Hemispherx Biopharma Inc (HEB):医療機器:M&Aディール及び事業提携情報
    Summary Hemispherx Biopharma Inc (Hemispherx) is a biopharmaceutical company, which develops, manufactures and commercializes drug therapies for the treatments of viral and immune based chronic disorders. It offers products for the treatment of various diseases such as hepatitis B, hepatitis C, chro …
  • Showa Denko Materials Co Ltd:企業の戦略的SWOT分析
    Showa Denko Materials Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Fives:企業の戦略・SWOT・財務分析
    Fives - Strategy, SWOT and Corporate Finance Report Summary Fives - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, provid …
  • Andritz AG (ANDR):企業の財務・戦略的SWOT分析
    Andritz AG (ANDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆